Pharmacologic treatment of adolescent and child schizophrenia

Expert Review of Neurotherapeutics

Volumn 4, Issue 1, 2004, Pages 53-60

  Young, Christopher M ^a   Findling, Robert L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antipsychotics; Atypical antipsychotics; Child and adolescent schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZATROPINE MESILATE; CLOZAPINE; HALOPERIDOL; LOXAPINE SUCCINATE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIHEXYPHENIDYL; ZIPRASIDONE;

AGRANULOCYTOSIS; APPETITE DISORDER; AUTONOMIC DYSFUNCTION; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; GALACTORRHEA; GYNECOMASTIA; HEART DISEASE; HUMAN; HYPERTHERMIA; MAINTENANCE THERAPY; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; ONSET AGE; PATIENT EDUCATION; PSYCHOTHERAPY; QT PROLONGATION; REVIEW; RIGIDITY; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0345862287     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.1.53     Document Type: Review

References (54)

1. Findling RI, Feeney NC, Stansbrey RL et al. Somatic treatment for depressive illnesses in children and adolescents. Child. Adolesc. Psych. Clin. N Am. 11, 555-578 (2002).
2. Clein PD, Riddle MA. Pharmacoeconomics in children and adolescents. Child Adolesent Psych. Clin. N. Am. (1995).
3. Cawthron P, James A, Dell J, Seagroart V. Adolescent onset psychosis. A clinical and outcome study. J. Child. Psychol. Psych. 35, 1321-1332 (1994).
4. Findling FJ, Schulz SC et al. Psychotic Disorders in Children and Adolescents. Sage Publications, Inc., CA, USA (2001).
5. Burd L, Kerbeshian J. A North Dakota prevalence study of schizophrenia presenting in childhood. J. Am. Acad. Child. Adolesc. Psych. 26, 347-350 (1987).
6. Beratis S, Gabriel J, Hoidas S. Age at onset in subtypes of schizophrenic disorders. Schizophr. Bull. 20, 287-296 (1994).
7. Hafner H, Maurer K, Loffler W, Reicher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br. J. Psych. 162, 80-86 (1993).
8. Gillberg IC, Hellgren L, Gillberg C. Psychotic disorders diagnosed in adolescence. Outcome at age 30 years. J. Child. Psychol. Psych. 34, 1173-1185 (1993).
9. Krausz M, Muller-Thomsen T. Schizophrenia with onset in adolescence: an 11-year follow-up. Schizophr. Bull. 19, 831-841 (1993).
10. McKenna K, Gordon CT, Lenane M, Kaysen D, Fahey K, Rapoport JL. Looking for childhood-onset schizophrenia: the first 71 cases screened. J. Am. Acad. Child Adolesc. Psych. 33, 636-644 (1994).
11. Alaaghband-Rad J, McKenna K, Gordon CT et al. Childhood-onset schizophrenia: the severity of premorbid course. J. Am. Acad. Child. Adolesc. Psych. 34, 1273-1283 (1995).
12. McClennan J, McCurry C, Snell J, Dubose A. Early-onset psychotic disorders: course and outcome over a 2-year period. J. Am. Acad. Child. Adolesc. Psych. 38, 1380-1388 (1999).
13. Ulloa RE, Birmaher B, Axelson D et al. Psychosis in children and adolescents: Phenomenology and correlates. J. Am. Acad. Child. Adolesc. Psych. 39, 337-345 (2000).
14. Volkmar FR. Childhood and adolescent psychosis: a review of the past 10 years. J. Am. Acad. Child. Adolesc. Psych. 35, 843-851 (1996). Comprehensive review of early onset psychosis.
15. Calderoni D, Wudarsky M, Bhangoo R et al. Differentiating childhood-onset schizophrenia from psychotic mood disorders. J. Am. Acad. Child. Adolesc. Psych. 40, 1190-1196 (2001).
16. Chambers WJ, Puigh-Antich J, Tabrizi MA et al. Psychotic symptoms in prepubertal major depressive disorder. Arch Gen. Psych. 921-927 (1982).
17. Caplan R, Tanguay PE. Development of psychotic thinking in children. In: Child and Adolescent Psychiatry a Comprehensive Textbook. Williams and Wilkins, Philadelphia, PA, USA, 315-322 (1996).
18. Kaufman J, Birmaher B, Clayton S et al. Trauma-related hallucinations in children. J. Am. Acad. Child. Adolesc. Psych. 36, 1602-1605 (1997).
19. Gunduz H, Alvir J, Woerner M et al. The impact of duration untreated psychosis symptoms on treatment response of delusions and hallucinations. Schiz. Res. 36, 18 (1999).
20. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatra. Scand. 81, 231-235 (1990).
21. McGlashan TH, Johanssen JO. Early detection and intervention with schizophrenia: rationale. Schizophr. Bull. 22, 201-222 (1996).
22. McGlashan TH. Early detection and intervention with schizophrenia: rationale and research. Br. J. Psych. 172, S3-S6 (1998).
23. McGorry P. The nature of schizophrenia: signposts to prevention. Aust. NZ J. Psych. 34, S14-S22 (2000).
24. McGorry PD, Yung AR, Phillips JL et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen. Psych. 59, 921-928 (2002). Early controlled trial aimed at prevention of psychotic illness.
25. Findling RL, Schulz SC, Reed MD, Blumer JL. The antipsychotics. A pediatric perspective. Ped. Clin. N. Am. 45, 1205-1232 (1998).
26. Campbell M, Spencer EK. Psychopharmacology in chills and adolescent psychiatry: a review of the past 5 years. J. Am. Acad. Child. Adolesc. Psych. 27, 269-279 (1988).
27. Pool D, Bloom W, Mielke DH, Roniger JJ Jr, Gallant DM. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr. Ther. Res. Clin. Ex. 19, 99-104 (1976). Early controlled trial of treatment of adolescents with schizophrenia.
28. Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am. J. Psych. 141, 440-442 (1984).
29. Spencer EK, Campbell M. Children with schizophrenia: diagnosis, phenomenology and pharmacotherapy. Schizophr. Bull. 20, 713-725 (1994).
30. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am. J. Psych. 154, 475-482 (1997). Highlights differences of early onset schizophrenia compared with adult onset.
31. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen. Psych. 40, 1113-1117 (1983).
32. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective longitudinal study. J. Am. Acad. Child. Adolesc. Psych. 36, 835-843 (1997).
33. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology Oct 29, (2003).
34. Kapur S, McClelland RA, VanderSpek SC et al. Increasing D2 affinity results in the loss of dozapine's atypical antipsychotic action. Neuroreport 13, 831-835 (2002).
35. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind dozapine halperidol comparison. Arch Gen. Psych. 53, 1090-1097 (1996).
36. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia. J. Am. Acad. Child. Adolesc. Psych. 36, 694-700 (1997).
37. Findling RL, McNamara NK, Gracious BL Paediatric uses of atypical antipsychotics. Expert. Opin. Pharmacol. 1, 935-945 (2000). Reviews atypical antipsychotics in pediatric patients.
38. Mandoki M. Olanzapine in the treatment of early-onset schizophrenia in children and adolescents. Biol. Psych. 41, S22 (1997).
39. Kumra S, Jacobsen LK, Lenane M et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents in adolescents. J. Am. Acad. Child. Adolesc. Psych. 37, 377-385 (1998).
40. Findling RI, McNamara NK, Youngstrom EA, Branicky LA, Demeter CA, Schulz SC. A prospective open-label trial of olanzapine in adolescents with schizophrenia. J. Am. Acad. Child. Adolesc. Psych. 42, 170-175 (2003).
41. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of Diabetes Mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psych. 159, 561-566 (2002).
42. Szigethy E, Brent S, Findling RL. Quetiapine for refractory for refractory schizophrenia. J. Am. Acad. Child. Adolesc. Psych. 37, 1127-1128 (1998).
43. Healy E, Subotsky F, Pipe R. Quetiapine in adolescent psychosis. J. Am. Acad. Child. Adolesc. Psych. 38, 1329 (1999).
44. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol. Bull. 29, 309-314 (1993).
45. McConville BJ, Arvanitis LA, Thyrum PT et al. Safety tolerability and effectiveness of quetiapine in adolescents with selected psychotic disorders: a long-term, open-label study. J. Child. Adolesc. Psychopharmacol. 10, 254-255 (2000).
46. Shaw JA, Lewis JE, Pascal S et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J. Child. Adolesc. Psychopharmacol. 11, 415-424 (2001).
47. Sallee FR, Kurlan R, Goetz CG et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J. Am. Acad. Child. Adolesc. Psych. 39, 292-299 (2000).
48. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and hatoperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psych. 63, 763-761 (2002).
49. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert. Opin. Pharmacother. 3, 1773-1781 (2002).
50. Birmaher B. Recognition and treatment of early-onset psychosis. Contemp. Psych. 1, 1-8 (2002).
51. Campbell M, Rapoport J, Simpson G. Antipsychotics in children and adolescents. J. Am. Acad. Child. Adolesc. Psych. 38, 537-545 (1999).
52. Gracious BL, Findling RL. Antipsychotic medications for children and adolescents. Ped. Ann. 30, 138-135 (2001).
53. Gutgesell H, Atkins D, Barst R et al. Scientific Statement: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J. Am. Acad Child. Adolesc. Psych. 38, 1047-1050 (1999).
54. Schaeffer JL, Ross RG. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J. Am. Acad. Child. Adolesc. Psych. 41, 538-545 (2002).